Menu Search
Equities

Marinomed Biotech AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
93Z:STU

Marinomed Biotech AG

Actions
  • Price (EUR)17.10
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+35.71%
  • Beta0.1703
Data delayed at least 15 minutes, as of Feb 17 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Marinomed Biotech AG's revenues fell -48.31% from 9.18m to 4.75m. a loss of 6.79m to a larger loss of 15.42m.
Gross margin65.35%
Net profit margin170.57%
Operating margin175.41%
Return on assets170.19%
Return on equity--
Return on investment--
More ▼

Cash flow in EURView more

In 2024, cash reserves at Marinomed Biotech AG fell by 900.00k. Cash Flow from Financing totalled 1.60m or 33.71% of revenues. In addition the company used 2.50m for operations while cash from investing was breakeven.
Cash flow per share9.21
Price/Cash flow per share2.00
Book value per share-3.06
Tangible book value per share-3.07
More ▼

Balance sheet in EURView more

Marinomed Biotech AG appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money.
Current ratio0.8334
Quick ratio--
Total debt/total equity--
Total debt/total capital2.03
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.